People · Operator
Named in public records as an officer, director or promoter · active 2017–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aktis Oncology, Inc. | — | Biotechnology | Series D+ | $175.0M | $1.8B | 2024 |
| Clear Creek Bio, Inc. | — | Biotechnology | Series A | $7.1M | $37.1M | 2017 |
Andrew S. Levin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew S. Levin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Todd Foley | 1 | 12 |
| Helen S. Kim | 1 | 6 |
| Matthew Roden | 1 | 3 |
| Oleg Nodelman | 1 | 3 |
| Burt S. Adelman | 1 | 1 |
| David S. Scadden | 1 | 1 |
| Vikram S. Kumar | 1 | 1 |
| Shulamit S. Ron-Bigger | 1 | 1 |
| Ken S. Herrmann | 1 | 1 |
| Lloyd S. Segal | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.